Novartis announced a definitive agreement to acquire Regulus Therapeutics, a clinical-stage biopharmaceutical company based in San Diego, focused on microRNA therapies. The acquisition centers on Regulus’ lead candidate, farabursen, a next-generation investigational treatment targeting miR-17 for autosomal dominant polycystic kidney disease (ADPKD). Farabursen has shown encouraging safety and efficacy results in a completed Phase 1b trial, including positive outcomes on key disease markers such as urinary polycystin and total kidney volume. The acquisition aligns with Novartis’ focus on kidney disease and builds upon its recent progress in the renal space.
Under the terms of the deal, Novartis will begin a tender offer to purchase all outstanding shares of Regulus common stock at USD 7 per share in cash, with an additional potential payout of up to USD 7 per share through a contingent value right based on future regulatory milestones. Upon completion, Regulus will become an indirect wholly owned subsidiary of Novartis. The transaction is expected to close in the second half of 2025, subject to regulatory approvals and standard closing conditions. This move supports Novartis' continued efforts in kidney health, following recent FDA approvals for treatments in IgA nephropathy and C3 glomerulopathy.
